影响生化转归为2型糖尿病的药物:系统综述与荟萃分析
该系统综述与荟萃分析纳入43项随机对照试验、共192,156名受试者(平均年龄60岁,56%为男性,平均BMI 30.4 kg/m2),评估多种药物对高危个体生化转归为2型糖尿病风险的影响。结果显示α-葡萄糖苷酶抑制剂、ACEI、ARB、二甲双胍、奥利司他、芬特明/托吡酯和吡格列酮显著降低风险,他汀类和那格列奈增加风险;磺脲类、GLP-1受体激动剂、DPP-4抑制剂和SGLT-2抑制剂直接证据不足。
要点
- 多种药物可改变高危人群生化转归为2型糖尿病的风险。
- 他汀类和那格列奈与生化转归风险增加相关。
- 多数试验疗程短且未设停药或洗脱期,证据有限。
核心结论
- 多种药物可改变生化转归为2型糖尿病的风险,但该效应是否持续及具有临床相关性尚不明确。
- 未来研究应关注心血管疾病预防、死亡率和患者重要结局,而非仅关注生化转归。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane对照试验中心注册库、Cochrane系统综述数据库和Scopus至2017年8月24日。
- 纳入43项随机对照试验,共192,156名受试者,平均年龄60岁,56%为男性,平均BMI 30.4 kg/m2。
主要发现
- α-葡萄糖苷酶抑制剂、ACEI、ARB、二甲双胍、奥利司他、芬特明/托吡酯和吡格列酮显著降低生化转归为2型糖尿病的风险。
- 他汀类和那格列奈增加生化转归为2型糖尿病的风险。
- 磺脲类、GLP-1受体激动剂、DPP-4抑制剂和SGLT-2抑制剂对生化转归风险的直接证据不足。
临床怎么用
- 对于2型糖尿病高危个体,可考虑使用被证实降低生化转归风险的药物,但需权衡长期获益与临床相关性。
- 他汀类和那格列奈可能增加生化转归风险,临床决策时应结合患者具体情况综合评估。
局限性
- 多数试验疗程短,且在治疗期间评估结局,未设停药或洗脱期。
- 生化转归为2型糖尿病的效应是否持续及具有临床相关性尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The extent to which some pharmacological interventions reduce or increase the risk of biochemical conversion to type 2 diabetes mellitus (T2DM) in at-risk individuals is unclear. METHODS: We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and Scopus through 24 August 2017 for randomized controlled trials evaluating the effect of drugs suspected to modify the risk of biochemical conversion to T2DM. RESULTS: We included 43 trials with 192,156 subjects (mean age, 60 years; 56% men; mean body mass index, 30.4 kg/m2). α-Glucosidase inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, metformin, orlistat, phentermine/topiramate, and pioglitazone significantly reduced the risk of biochemical conversion to T2DM, whereas statins and nateglinide increased the risk. There was insufficient direct evidence regarding the effects of sulfonylureas, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors. Most trials were brief and evaluated this outcome during treatment without a withdrawal or washout period. CONCLUSIONS: Several drugs modify the risk of biochemical conversation to T2DM, although whether this effect is persistent and clinically relevant is unclear. Future studies need to focus on cardiovascular disease prevention, mortality, and patient-important outcomes instead of biochemical conversion to T2DM.
引用
- Domecq JP, Prutsky G, Elraiyah T, et al. Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2019. PMID: 31365088. doi:10.1210/jc.2019-01269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。